Global tech market leader expands fleet of ActivPanel displays, launching two new displays, to ensure every school and district, no matter the tech and budget parameters, can integrate advanced solutions SEATTLE, June 9, 2025 /PRNewswire/ -- Promethean, a leading global tech company and brand owned by Mynd.ai, Inc. (NYSE American: MYND), announces an expansion of its award-winning ActivPanel display portfolio. Alongside ActivPanel 10 and ActivPanel 10 Premium, Promethean is globally launching two additional ...

Leading tech company to highlight new ActivPanel 10 Premium experience with DisplayNote Launcher software for the workplace at InfoComm 2025SEATTLE, June 2, 2025 /PRNewswire/ -- Promethean, a leading global tech company and award-winning brand owned by Mynd.ai, Inc. (NYSE American: MYND), is shaking up the tech industry with the latest solutions in workplace technology and meeting collaboration. With more than 71 million meeting rooms and breakout spaces to fill in workplace industries around the globe,* IT ...

The new Promethean Chromebox OPS turns large interactive touchscreens into ChromeOS devices. The simple plug-in device offers a supported and certified ChromeOS experience without navigating cables or requiring educators to take extra steps when accessing files and content. Promethean partners with Google on powerful plug-in ChromeOS device Promethean partners with Google on powerful plug-in ChromeOS device "Installing the new Chromebox OPS is simple because it fits right into an ActivPanel, giving ChromeOS ...

SEATTLE, May 1, 2025 /PRNewswire/ -- Promethean, a leading global tech company and brand owned by Mynd.ai, Inc. (NYSE American: MYND), took home the Red Dot Design Award 2025 for the ActivPanel 10 Premium, the company's next-generation interactive flat panel display (IFPD).The Red Dot Design Award was established in 1955 and is one of the world's largest, most well-known design competitions. The independent Red Dot Jury assesses all entries based on four key principles of good design—the quality of function ...

SEATTLE, April 9, 2025 /PRNewswire/ -- Mynd.ai, Inc. ("Mynd" or the "Company") (NYSE American: MYND), a global leader in interactive hardware and software solutions for education and enterprise, today announced that Vin Riera, Chief Executive Officer, will be stepping down from his role as CEO effective April 11, 2025, after eight years of exceptional leadership in the role. He has also resigned as a member of the Company's Board of Directors. Arthur Giterman, Mynd's current Chief Financial Officer, has bee ...

Highlights Include Sale of a Non-strategic Business Unit, Significant Reduction of Debt, and Implementation of a Share Repurchase Program to Strengthen the Company and Enhance Long Term Shareholder Value  SEATTLE, March 26, 2025 /PRNewswire/ -- Mynd.ai, Inc. (the "Company" or "Mynd") (NYSE American: MYND) today announced financial results for the fiscal year ended December 31, 2024. Revenue of $267.4 million for the full year, compared to $411.8 million in the prior year with the decrease primarily driven ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Vancouver, British Columbia--(Newsfile Corp. - February 11, 2025) - MYND Life Sciences Inc. (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that it has entered into shares for debt agreements (the "Agreements"), to satisfy an aggregate of $2,273,062.30 of the Company's outstanding debt (the "Indebtedness") ...

Company Announcement - MYND Life Sciences has approved the issuance of 4,000,001 common shares at $0.71 per share to settle a $3.5 million (CDN) debenture [1] - The issuance of shares for a total value of $2,840,000.71 has been completed, marking a significant inflection point for the company [2] - The details of the debenture settlement will be reflected in MYND's upcoming financial statements [3] Business Focus - MYND Life Sciences is a clinical-stage life sciences company focused on developing drug therapies and a proprietary biomarker test for Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD) [4] - The company's proprietary biomarker for depression aims to support personalized patient management strategies and offers near-term revenue opportunities [4] - MYND is developing the first test of its kind targeting depression, addressing a significant unmet need in the market [4]

Company Updates - Colin Campbell has stepped down as CEO after successfully repositioning the company for future success and retiring the debenture He will remain as a Director and assist in identifying a new CEO to lead the company through the clinical testing phase and commercialization of its proprietary biomarker test for depression [1] - The company successfully retired its debenture removing $3 5 million (CDN) of debt from its balance sheet This milestone reflects the company's strategic focus on developing the first depression biomarker test [4][5] Company Overview - MYND Life Sciences Inc is a clinical-stage life sciences company focused on developing and commercializing a proprietary biomarker test for diagnosing and monitoring Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD) The company aims to be the first to market with this innovative test addressing a significant unmet need in depression management [2] - The company's proprietary biomarker test leverages unique intellectual property (IP) and has the potential to generate near-term revenues by driving personalized patient management strategies [2]